Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/5585
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCrowe Aen
dc.contributor.authorMcMahon Nen
dc.contributor.authorCurrie BJen
dc.contributor.authorBaird RWen
dc.date2014en
dc.date.accessioned2018-05-15T23:01:16Zen
dc.date.available2018-05-15T23:01:16Zen
dc.date.issued2014-08en
dc.identifier.citationInternational journal of antimicrobial agents 2014-08; 44(2): 160-2en
dc.identifier.urihttps://hdl.handle.net/10137/5585en
dc.description.abstractBurkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.en
dc.language.isoengen
dc.subjectAntimicrobial susceptibilityen
dc.subjectBurkholderia pseudomalleien
dc.subjectMelioidosisen
dc.titleCurrent antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia.en
dc.typeJournal Articleen
dc.typeResearch Support, Non-U.S. Gov'ten
dc.identifier.journaltitleInternational journal of antimicrobial agentsen
dc.identifier.doi10.1016/j.ijantimicag.2014.04.012en
dc.identifier.pubmedidhttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed//24924662en
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshBurkholderia pseudomalleien
dc.subject.meshCeftazidimeen
dc.subject.meshDrug Resistance, Bacterialen
dc.subject.meshHumansen
dc.subject.meshMelioidosisen
dc.subject.meshMicrobial Sensitivity Testsen
dc.subject.meshNorthern Territoryen
dc.subject.meshRoot Cause Analysisen
dc.subject.meshThienamycinsen
dc.subject.meshTrimethoprim, Sulfamethoxazole Drug Combinationen
dc.identifier.affiliationMicrobiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia..en
dc.identifier.affiliationMicrobiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia..en
dc.identifier.affiliationInfectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT 0810, Australia..en
dc.identifier.affiliationMicrobiology Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia; Infectious Diseases Department, Royal Darwin Hospital, Rocklands Drive, Tiwi, NT 0810, Australia. Electronic address: rob.baird@nt.gov.au..en
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing